19年09月25日，Tianjin Biological announced that it has reached a strategic cooperation with Sanofi on the development, production, and commercialization of its independently developed global innovative CD73 antibody urelumab in the Greater China region. Sanofi will pay Tianjin Biological approximately 32 million euros as an upfront payment and near-term milestone payments, as well as specific registration and sales milestone payments; the potential total consideration will not exceed 213 million euros.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Tianjing Biology has authorized protocol with Sanofi, with a potential total price of up to 200 million euros.
19年09月25日，Tianjin Biological announced that it has reached a strategic cooperation with Sanofi on the development, production, and commercialization of its independently developed global innovative CD73 antibody urelumab in the Greater China region. Sanofi will pay Tianjin Biological approximately 32 million euros as an upfront payment and near-term milestone payments, as well as specific registration and sales milestone payments; the potential total consideration will not exceed 213 million euros.